Vistagen Therapeutics Inc (VTGN) Stock Price, Quote & News

Company Profile

Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company's product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an odorless synthetic investigational neuroactive pherine nasal spray, which is in Phase II clinical trial...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 577 3600

Website: www.vistagen.com

Address:

343 Allerton Avenue, South San Francisco, United States

RemoteInvestor Aug. 21 at 3:07 PM

$VTGN beautiful 3 months chart. Now we are climbing again. The trend is our friend!

0 · Reply

kimgysen Aug. 21 at 2:20 PM

$VTGN One bearish engulfment after the other. Strange stock lol... but looks like Batman formation, dangerous games

0 · Reply

Lstreak Aug. 20 at 5:53 PM

$VTGN Consolidating up nicely also $IPOOF, & $RSSS.

0 · Reply

Haimalon Aug. 20 at 2:49 PM

$VTGN The a logarithm is working hard, every time it try to recover , boom the alogarithm is purring chip stocks

0 · Reply

MakesHerSquirt Aug. 20 at 2:46 PM

$VTGN Picked up another 1k shares. Thank you!!!! You will regret not loading up at this price

0 · Reply

Stockrunner54 Aug. 20 at 2:19 PM

$VTGN kinda pissed we pulled back this hard. However I think the XBI and spy pullback had something to do with it. Oh well. Let’s hold support and rally again into end of month.

1 · Reply

BioBum Aug. 20 at 2:06 PM

$VTGN that recent wave up was a short closing the position. I expect a drop and bounce in the coming week

1 · Reply

Ruzmadji Aug. 19 at 7:16 PM

$VTGN back to $3.50 LMAO

2 · Reply

Stockrunner54 Aug. 19 at 6:36 PM

$VTGN going to be funny when it gaps above 4$ out of nowhere. flippers will be left behind, or wanting to buy higher! imo.

0 · Reply

gramirez Aug. 19 at 5:34 PM

$VTGN amazing last days!!! today is an opportunity to improve the avg... go ahead!!!

0 · Reply

Vistagen Therapeutics, Inc. (VTGN) Q1 2026 Earnings Call Transcript

Aug 7, 2025, 4:30 PM EDT - 13 days ago

Vistagen Reports Fiscal Year 2026 First Quarter Financial Results and Corporate Update

Jul 31, 2025, 8:30 AM EDT - 21 days ago

Vistagen to Report Fiscal Year 2026 First Quarter Results and Host Corporate Update Conference Call on August 7, 2025

Jul 24, 2025, 8:30 AM EDT - 4 weeks ago

Vistagen to Present at the BTIG Virtual Biotechnology Conference

Jul 15, 2025, 8:30 AM EDT - 5 weeks ago

Vistagen Honored for Outstanding Workplace Culture and Mental Health Leadership

Jun 25, 2025, 8:30 AM EDT - 2 months ago

Vistagen Appoints Elissa Cote as Chief Corporate Development Officer

Jun 17, 2025, 6:49 PM EDT - 2 months ago

Vistagen Therapeutics, Inc. (VTGN) Q4 2025 Earnings Call Transcript

Jun 17, 2025, 4:30 PM EDT - 2 months ago

Vistagen Reports Fiscal Year 2025 Financial Results and Provides Corporate Update

Jun 12, 2025, 8:30 AM EDT - 2 months ago

Vistagen to Report Fiscal Year 2025 Financial Results and Host Corporate Update Conference Call on June 17, 2025

Jun 2, 2025, 8:30 AM EDT - 2 months ago

Vistagen on Track to Deliver Topline Data From Fasedienol PALISADE-3 Phase 3 Trial for Acute Treatment of Social Anxiety Disorder in the Fourth Quarter of This Year

May 28, 2025, 8:30 AM EDT - 3 months ago

Vistagen to Present at the Jefferies 2025 Global Life Sciences Conference New York

May 23, 2025, 8:30 AM EDT - 3 months ago

Vistagen to Present at the 2025 American Society of Clinical Psychopharmacology Conference

Apr 17, 2025, 8:30 AM EDT - 4 months ago

Vistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 Conference

Mar 19, 2025, 8:30 AM EDT - 5 months ago

Vistagen to Present at the 2025 Anxiety and Depression Association Conference

Mar 4, 2025, 8:30 AM EST - 6 months ago

Vistagen to Participate in Stifel 2025 Virtual CNS Forum

Feb 20, 2025, 8:30 AM EST - 6 months ago

Vistagen to Participate in the 45th Annual TD Cowen Healthcare Conference

Feb 14, 2025, 6:19 PM EST - 6 months ago

Vistagen: Pherine Candidate Proof Of Concept Continues With Fifth Indication

Feb 13, 2025, 8:47 PM EST - 6 months ago

Vistagen Therapeutics, Inc. (VTGN) Q3 2025 Earnings Call Transcript

Feb 13, 2025, 4:30 PM EST - 6 months ago

Vistagen Reports Fiscal Year 2025 Third Quarter Financial Results and Corporate Update

Feb 6, 2025, 8:30 AM EST - 7 months ago

Vistagen to Report Fiscal Year 2025 Third Quarter Results and Host Corporate Update Conference Call on February 13, 2025

Feb 5, 2025, 8:30 AM EST - 7 months ago

Vistagen Receives U.S. Patent for AV-101 to Treat Neuropathic Pain

Jan 14, 2025, 8:30 AM EST - 7 months ago

Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH284 in Cancer Cachexia

Jan 10, 2025, 8:30 AM EST - 7 months ago

Vistagen Initiates Fasedienol Repeat Dose Study for the Acute Treatment of Social Anxiety Disorder

Nov 14, 2024, 8:30 AM EST - 10 months ago

Vistagen to Present at the Stifel 2024 Healthcare Conference

Nov 10, 2024, 7:43 AM EST - 10 months ago

Vistagen Therapeutics, Inc. (VTGN) Q2 2025 Earnings Call Transcript

Nov 7, 2024, 4:20 PM EST - 10 months ago

Vistagen Reports Fiscal Year 2025 Second Quarter Financial Results and Corporate Update

Nov 5, 2024, 8:30 AM EST - 10 months ago

Vistagen to Present at the 2024 Neuroscience Education Institute Congress

Nov 1, 2024, 8:30 AM EDT - 10 months ago

Vistagen to Report Fiscal Year 2025 Second Quarter Results and Host Corporate Update Conference Call on November 7, 2024

Oct 15, 2024, 7:25 AM EDT - 11 months ago

Vistagen Could Run Up Ahead Of Phase 3 Results In Social Anxiety Disorder

Oct 9, 2024, 8:30 AM EDT - 11 months ago

Vistagen, The Goldie Hawn Foundation, and MindUP Students to Ring Nasdaq Closing Bell on World Mental Health Day

Sep 23, 2024, 8:30 AM EDT - 11 months ago

Vistagen Initiates PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder

Aug 13, 2024, 7:05 PM EDT - 1 year ago

Vistagen Therapeutics, Inc. (VTGN) Q1 2025 Earnings Call Transcript

Aug 13, 2024, 4:21 PM EDT - 1 year ago

Vistagen Reports Fiscal Year 2025 First Quarter Financial Results and Corporate Update

Aug 6, 2024, 8:30 AM EDT - 1 year ago

Vistagen to Report Fiscal Year 2025 First Quarter Results and Host Corporate Update Conference Call on August 13, 2024

Jul 9, 2024, 8:30 AM EDT - 1 year ago

Vistagen Broadens PH80 Global Intellectual Property Portfolio with New Patents for the Treatment of Migraine

Jun 27, 2024, 8:30 AM EDT - 1 year ago

Vistagen Awarded Mental Health America's Platinum Bell Seal for Workplace Mental Health for the Second Consecutive Year

Jun 11, 2024, 6:41 PM EDT - 1 year ago

Vistagen Therapeutics, Inc. (VTGN) Q4 2024 Earnings Call Transcript

Jun 11, 2024, 4:20 PM EDT - 1 year ago

Vistagen Reports Fiscal Year 2024 Financial Results and Provides Corporate Update

Jun 7, 2024, 8:30 AM EDT - 1 year ago

Vistagen to Report Fiscal Year 2024 Financial Results and Host Corporate Update Conference Call on June 11, 2024

May 29, 2024, 8:30 AM EDT - 1 year ago

Vistagen to Present at the Jefferies Global Healthcare Conference

May 23, 2024, 8:30 AM EDT - 1 year ago

Vistagen to Present at the 2024 American Society of Clinical Psychopharmacology (ASCP) Conference

May 7, 2024, 8:30 AM EDT - 1 year ago

Vistagen to Present at the 2024 RBC Capital Markets Global Healthcare Conference

Apr 25, 2024, 8:30 AM EDT - 1 year ago

Vistagen Announces Positive Results from Phase 2A Pilot Study of PH15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue

Apr 9, 2024, 8:30 AM EDT - 1 year ago

Vistagen to Present at the 2024 Anxiety and Depression Association (ADAA) Conference

Apr 1, 2024, 8:30 AM EDT - 1 year ago

Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2

Mar 20, 2024, 9:01 PM EDT - 1 year ago

Vistagen Therapeutics: Initial Analysis Of Fasedienol Points To Bullish

Mar 17, 2024, 3:07 AM EDT - 1 year ago

Why VistaGen Therapeutics Is A Buy: Fasedienol Potential For Anxiety Treatments

Mar 15, 2024, 2:33 PM EDT - 1 year ago

This overlooked corner of women's health could be a $350 billion market opportunity

PFE PGNY BTMD DARE

Mar 11, 2024, 8:30 AM EDT - 1 year ago

Vistagen to Present at Stifel 2024 Virtual CNS Days

Feb 28, 2024, 8:30 AM EST - 1 year ago

Vistagen to Present at TD Cowen 44th Annual Health Care Conference

RemoteInvestor Aug. 21 at 3:07 PM

$VTGN beautiful 3 months chart. Now we are climbing again. The trend is our friend!

0 · Reply

kimgysen Aug. 21 at 2:20 PM

$VTGN One bearish engulfment after the other. Strange stock lol... but looks like Batman formation, dangerous games

0 · Reply

Lstreak Aug. 20 at 5:53 PM

$VTGN Consolidating up nicely also $IPOOF, & $RSSS.

0 · Reply

Haimalon Aug. 20 at 2:49 PM

$VTGN The a logarithm is working hard, every time it try to recover , boom the alogarithm is purring chip stocks

0 · Reply

MakesHerSquirt Aug. 20 at 2:46 PM

$VTGN Picked up another 1k shares. Thank you!!!! You will regret not loading up at this price

0 · Reply

Stockrunner54 Aug. 20 at 2:19 PM

$VTGN kinda pissed we pulled back this hard. However I think the XBI and spy pullback had something to do with it. Oh well. Let’s hold support and rally again into end of month.

1 · Reply

BioBum Aug. 20 at 2:06 PM

$VTGN that recent wave up was a short closing the position. I expect a drop and bounce in the coming week

1 · Reply

Ruzmadji Aug. 19 at 7:16 PM

$VTGN back to $3.50 LMAO

2 · Reply

Stockrunner54 Aug. 19 at 6:36 PM

$VTGN going to be funny when it gaps above 4$ out of nowhere. flippers will be left behind, or wanting to buy higher! imo.

0 · Reply

gramirez Aug. 19 at 5:34 PM

$VTGN amazing last days!!! today is an opportunity to improve the avg... go ahead!!!

0 · Reply

RemoteInvestor Aug. 19 at 4:21 PM

$VTGN phantastic opportunity to accumulate. Getting greedy...

0 · Reply

Halg_fr Aug. 19 at 2:39 PM

$VTGN take it or leave it. This is your opportunity to build a bigger position.

0 · Reply

Stockrunner54 Aug. 19 at 1:49 PM

$VTGN not getting mine!

0 · Reply

GETT Aug. 19 at 1:12 PM

$VTGN LET’S ROCK!

0 · Reply

RemoteInvestor Aug. 19 at 12:55 PM

$VTGN we talk about a new class of medicines with no side effects! https://psychiatryonline.org/doi/10.1176/appi.ajp-rj.2024.200208

0 · Reply

jsonme24 Aug. 19 at 10:19 AM

$VTGN when are we heading for fda approval

2 · Reply

HoHoHoHum Aug. 19 at 9:29 AM

$VTGN looks like we are building momentum

0 · Reply

Stockrunner54 Aug. 19 at 4:58 AM

$VTGN chatgpt: how much of $VTGN's outstanding share count is owned by institutions approximately. "As of mid-2025, around half to slightly more than half of VTGN’s outstanding shares (~50–55%) are held by institutional investors."

1 · Reply

BioBum Aug. 19 at 2:33 AM

$VTGN all we need is a phase 3 pass to open up NOT ONLY anxiety treatment, but a novel molecule that has potential to treat a wide range of diseases. Depression, PMS, mental fatigue, cachexia. 2B+ market cap easily. Would put the stock at $60+

2 · Reply

StockScanners Aug. 19 at 12:42 AM

$VTGN reached 3.58

0 · Reply

MakesHerSquirt Aug. 18 at 9:29 PM

$VTGN I was able to get out of this at $18 last readout. Hoping I can replay that former glory

1 · Reply

RemoteInvestor Aug. 18 at 8:34 PM

$VTGN buyout on the horizon? Not very likely imo but partnership with option agreement is possible!

0 · Reply

Market Cap	97.26M
Revenue (ttm)	490,000.00
Net Income (ttm)	-51.42M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-10,493.88%
Debt to Equity Ratio	0.00

Volume	521,100
Avg Vol	470,418
Day's Range	N/A - N/A
Shares Out	30.68M
Stochastic %K	44%
Beta	0.40
Analysts	Strong Sell
Price Target	$13.00